POST Online Media Lite Edition



 

Quest Diagnostics acquires PhenoPath

Staff Writer |
Quest Diagnostics announced that it has acquired PhenoPath, a national provider of specialized anatomic pathology (AP) and related services.

Article continues below




Based in Seattle, PhenoPath provides AP, molecular oncology and other services that complement and extend those of the company's Advanced Diagnostics portfolio of services. These include services, such as genetic sequencing and genomic tumor analysis, which require higher-order expertise and skill.

The PhenoPath business will operate as part of AmeriPath, a wholly owned business of Quest Diagnostics. The leading provider of anatomic pathology services, AmeriPath provides high-end pathology services to many ambulatory health and surgery centers, imaging centers, clinics and physician offices, and has on-site community pathologists in more than 170 hospitals across the country.

AP and molecular oncology services are essential to diagnose many diseases, particularly cancer. In 2018, there will be an estimated 1,735,350 new cancer cases diagnosed in the United States, according to the American Cancer Society.

Additional terms of the transaction were not disclosed.


What to read next

Quest Diagnostics hacked, 34,000 health records exposed
Quest to buy Solstas for $570 million
DiaSorin to acquire Focus Diagnostics' businesses for $300 million